Arthur D. Little Publishes Special 135th Anniversary Edition of PRISM Magazine
17.12.2021 17:11:00 EET | Business Wire | Press release
Arthur D. Little (ADL) has published Who Says It Can’t Be Done? – the latest edition of its innovation magazine PRISM. As well as celebrating the company’s 135-year history, this special edition looks ahead to both the future of business and the consulting industry itself.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005298/en/
Arthur D. Little Prism Magazine (Photo: Business Wire)
The magazine features five key articles:
- Rebalancing For Tomorrow – The ability to help clients anticipate the future, embrace new opportunities, and transform their operations has always been a central part of ADL’s consulting philosophy. This article looks at the challenges that business faces today, identifies important priorities for the future, and reflects on how companies can get ready to meet them.
- Why Consultancy Matters: A Historical Perspective – What is the exact nature of management consultancy’s value? Does consulting merely provide a similar service to that of the accountancy or legal professions, or does it provide a different type of value? This article explores how management consultancy has helped to shape the world we live in today as illustrated by the history of ADL.
- The Future Of Consultancy – In today’s volatile environment, companies are looking for more than just me-too solutions to remain competitive. The consulting industry needs to reconfigure its approach and reject obsolete legacy models if it is to stay relevant to modern business. This article looks at some of the ways in which consulting must change in order to create real value for its clients.
- Inventors, Innovators, Pathfinders – Since the days of Arthur Dehon Little himself, ADL has been driven by hugely talented individuals, all pathfinders in their own right. This article celebrates some of the extraordinary people who have both led ADL and pioneered its unique approach to consultancy, inventing new solutions and breaking down barriers along the way.
- Who Says It Can’t Be Done? – It was only after a management buyout (MBO) on 30 December 2011 that ADL was truly reborn as a successful partnership with a rapidly expanding business. In this interview with Ignacio Garcia-Alves, who led the MBO and has been ADL’s Chief Executive Officer ever since, he shares his insights on how the company was transformed and the lessons learned over the past ten years.
Ignacio García Alves, Global Chairman and Chief Executive Officer of Arthur D. Little, comments: “PRISM always offers the best in thought-leading insight and commentary on the key topics of the day, and this edition is no exception – but with ADL hitting the milestone of 135 years of constant innovation, we couldn’t resist also looking back on what’s made it such a unique and pioneering company.”
This latest edition of PRISM can be viewed here: https://tinyurl.com/9hyefpch
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005298/en/
Contact information
Further information from: Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom